QuantaFlo HD Clinical Validation Study

Conditions

• To Assess Cardiovascular Function

Eligibility Criteria

Sex

ALL

Age

22 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• QuantaFlo HD — DEVICE
  blood flow at the finger during a forced expiration

Study Details

The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.

Key Dates

Start date

Aug 21, 2025

Status verified

Oct 2025

Primary completion

Mar 31, 2026

Completion

Jun 30, 2026

Study Design

Enrollment

600 participants (estimated)

Primary Outcome Measure

Sensitivity and Specificity [ Time Frame: From enrollment to the end of treatment is up to 1 week ]

Central Contacts

• Gena Parker
  669-230-2729
  [email protected]

Locations (1)

Find similar trials in Tucson, AZ